Atossa Therapeutics, Inc. (ATOS) analyst actions
Rating and price-target actions on ATOS in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the ATOS overview →
2 measured ATOS analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program | Press release | +4.77% | +5.96% | |
| Quantum Leap Healthcare Collaborative Initiates Landmark Phase 2 RECAST DCIS Platform Trial to Evaluate Alternative DCIS Treatments with Atossa Therapeutics, Havah Therapeutics, and the Menarini Group | Press release | +2.29% | +0.51% |
Keep exploring
More ATOS: earnings → · SEC filings → · ATOS overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| EKIMAS CORPORATION (ASNB) | 223 | 0.00% | 45% |
| OASMIA PHARMACEUTICALS AB AMERICAN DEPOSITARY SHARE (OASM) | 223 | 0.00% | 35% |
| FibroGen, Inc (FGEN) | 220 | -0.50% | 45% |
| INNOVATE BIOPHARMACEUTICALS (INNT) | 220 | -0.77% | 38% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.